R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
Phase 1
18
about 5.7 years
0.25–26
1 site in NY
What this study is about
This trial is testing the safety and feasibility of giving R-MVST cells to people with severe viral infections like Epstein-Barr Virus, cytomegalovirus, adenovirus, or BK virus. The treatment involves generating T cells that fight viruses on demand from healthy donors who are a close match for the patient. Researchers will carefully watch patients for any side effects, such as graft-versus-host disease after the infusion.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Rapidly generated virus specific T (R-MVST) cells
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence of toxicity that leads to safety endpoint
Secondary: Overall survival rate, Percentage of subjects with good response in viral load or end-organ disease improvement
Immune, Infectious